Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia

Studd, Corrie; Cameron, G. R.; Beswick, Lauren; Knight, Ross; Hair, Christopher; McNeil, John J; Desmond, Paul; Wilson, Jarrad; Connell, W. K.; Bell, Sally

doi:10.1111/jgh.13050

Cited by 51 publications

(52 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Crude IBD, CD, UC and IBDU 1‐year incidence rates in our study were also comparable with previous Australasian data. Data from Barwon in 2010–2011 report an incidence of 24.2, 14.7, 7.5 and 2.0 per 100 000 respectively . The 95% CIs for crude IBD incidence rates per 100 000 in the most recent Barwon data (18.9, 30.5) and our study (24.4, 33.7) overlapped, suggesting no significant difference in incidence across Australian regions.…”

Section: Discussionsupporting

confidence: 38%

“…Prevalence rates of IBD in our study were comparable with previous Australasian data. Data from Barwon in 2010–2011 report similar crude 12‐month period prevalence rates for IBD, CD, UC and IBDU of 344.6, 197.3, 136 and 8.5 per 100 000 respectively . In Canterbury, crude point prevalence rates on 1 June 2005 were 308.2, 155.2, 145.0 and 8.0 per 100 000 respectively .…”

Section: Discussionmentioning

confidence: 89%

“…Gearry et al reported on IBD epidemiology in the Canterbury region of New Zealand in 2006 and 2014 . Wilson et al, Studd et al and Niewiadomski et al conducted similar research in the Barwon region of Victoria, Australia, between 2010 and 2016. These studies report epidemiological rates similar to Northern Europe and America, which are among the highest in the world.…”

Section: Introductionmentioning

confidence: 92%

See 2 more Smart Citations

Inflammatory bowel disease incidence, prevalence and 12‐month initial disease course in Tasmania, Australia

Bhatia

Yeoh

Vaz

et al. 2019

Internal Medicine Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 38%

Section: Discussionmentioning

confidence: 89%

Section: Introductionmentioning

confidence: 92%

See 1 more Smart Citation

Inflammatory bowel disease incidence, prevalence and 12‐month initial disease course in Tasmania, Australia

Bhatia

Yeoh

Vaz

et al. 2019

Internal Medicine Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…We also observed that disease presentation at diagnosis did not change significantly over the study period, which has been reported elsewhere [31]. However, an increase in the proportion of cases with L3 disease location over time was reported between 2007/2008 and 2010/2011 in the same area of neighbouring Australia, but the number of cases with complete disease location data was relatively small [24]. Nevertheless, this observation may be real, and although there is no clear explanation for this increase, investigation of the length of the small intestine has proven problematic and spurred the rapid evolution and introduction of methods for visualising the small intestine with minimal invasion.…”

Section: Discussionmentioning

confidence: 54%

“…In recent years, different studies from around the world have reported annual IBD incidence rates were increasing, plateauing or even decreasing [14,17,24]. While Asia-based population studies continue to show increasing IBD incidence rates, two recent Eastern Canadian studies found statistically significant reductions in IBD incidence among populations with previously high rates [11,13,14,25,26], whereas two separate Danish studies, conducted during a time period similar to that of our study, both observed increases in CD incidence and UC incidence in both men and women [27,28].…”

Section: Discussionmentioning

confidence: 99%

Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis

Coppell¹,

Galts²,

Huizing³

et al. 2018

Inflamm Intest Dis

View full text Add to dashboard Cite

Background: The aim of this study was to describe the incidence of inflammatory bowel disease (IBD) and changes in demographic and phenotypic disease presentation in Otago, New Zealand. Methods: This study was conducted at Dunedin Hospital and the study period was 1996–2013. Otago residents diagnosed with IBD were identified retrospectively from hospital lists using ICD-10 codes. Diagnosis, and place and date of diagnosis, were confirmed using medical notes and histology reports. Demographic, clinical and diagnostic data were recorded. Age-standardised incidence rates were estimated and trends over time assessed. Multinomial logistic regression was used to assess evidence for any changes in the distribution of disease location for Crohn’s disease (CD) cases. Results: The diagnosis of IBD was confirmed in 224 males and 218 females, and most were New Zealand European. Of the total number of confirmed IBD cases, 40.0% were ulcerative colitis (UC), 52.1% were CD and 7.9% were IBD unclassified. The age distribution illustrated bimodal peaks at 20–24 years and 65–69 years. Incidence rates varied from year to year, but there was no statistically significant change over the 18-year study period. The estimated age-standardised IBD incidence varied between 5.8/100,000 in 2006 and 29.8/100,000 in 2012. The incidence rates for UC and CD were 2.8/100,000 and 1.8/100,000, respectively, in 2006 and 6.3/100,000 and 21.8/100,000, respectively, in 2012. There were no significant phenotypic changes in CD patients over the study period. Conclusions: The IBD incidence in Otago, New Zealand, is high compared to many other countries. Annual age-standardised incidence rates vary, highlighting the limitations of single-year incidence data.

show abstract

Addressing pregnancy‐related concerns in women with inflammatory bowel disease: Insights from the patient's perspective

et al. 2020

View full text Add to dashboard Cite

Background and Aim: Therapeutic options for inflammatory bowel disease (IBD) have expanded, as has the use of IBD medications in women during the reproductive period. However, no qualitative data exist that examine the pregnancy-related concerns of women with IBD in the current era of widespread immunomodulator and biologic use. Hence, we aimed to explore in detail the impact of IBD on pregnancy from the patient's perspective. Methods: This qualitative study used semistructured interviews to explore participants' experiences regarding IBD and pregnancy until no new themes emerged. Key themes were identified using thematic analysis. Results: Fifteen women with IBD were interviewed. The majority of participants reported lingering concerns regarding their IBD medications, despite advice from their gastroenterologist that the drugs were considered safe in pregnancy. Participants more often reported medication-related fears, such as potential negative effects on their child's immune system, than concerns regarding the effect of the disease itself on their pregnancy outcomes. A common theme was a perceived lack of knowledge among non-IBD clinicians regarding IBD medications during pregnancy, which augmented pre-existing anxiety. Conclusions: This study is the first of its kind to provide an in-depth assessment of female patients' perspectives of IBD in relation to conception, pregnancy, and caring for offspring. In particular, this research characterizes the unique fears and persisting anxieties regarding IBD medications in pregnancy. The study has unearthed important insights into the specific concerns and support needs of women with IBD in order to facilitate nonjudgmental counseling designed around patient concerns and beliefs.

show abstract

Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australia

Cited by 51 publications

References 28 publications

Inflammatory bowel disease incidence, prevalence and 12‐month initial disease course in Tasmania, Australia

Inflammatory bowel disease incidence, prevalence and 12‐month initial disease course in Tasmania, Australia

Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis

Addressing pregnancy‐related concerns in women with inflammatory bowel disease: Insights from the patient's perspective

Contact Info

Product

Resources

About